Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISL/LEN vs B/F/TAF in Virologically Suppressed People With HIV-1
NCT06630286Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of islatravir and lenacapavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of Participants with HIV-1 RNA >= 50 Copies/mL at 48 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
islatravirlenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06630286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630286.